Company intelligence / Profile preview

BIND Therapeutics

Cambridge, Massachusetts, United Statespfizer.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

BIND-014 completed enrollment in Phase 2 iNSITE 1 trial for NSCLC with squamous histology, with data expected by end of Q1 2016. The iNSITE 2 trial for advanced cervical cancer and head and neck cancer completed enrollment of at least 20 patients in each cohort in the first stage[9]. AZD2811, an Aurora B kinase inhibitor, entered Phase 1 clinical trials for solid tumors in 2015[6].

Therapeutic areas: Oncology
Modalities: Nanomedicinetargeted therapeutics
Industry: Biotech

Drug pipeline

2 assets

BIND-014

Phase 2

Indications: Metastatic castration-resistant prostate cancer, Solid tumors

1 more asset in the full pipeline.

Request access →

Partnerships

AstraZenecaSynergy Pharmaceuticals

Beyond the preview

Go deeper on BIND Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIND Therapeutics.

Explore the full profile